Tom Spurling – Executive Director – Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Copyright 2023 – Finance News Network
23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
05 Jul 2021 - icetana Limited (ASX:ICE) CEO & Managing Director Matt Macfarlane talks about the company's AI software, which dramatically improves active security monitoring by learning normal movement patterns and highlighting abnormal movement in real time.
02 Mar 2020 - Integrated Payment Technologies Limited (ASX:IP1) CEO, Dean Martin, discusses 1H20 results, customers numbers and take up for the company's ClickSuper and PayVu systems and integration with accounting platforms.
03 Aug 2020 - Kingston Resources Limited (ASX:KSN) Managing Director Andrew Corbett provides an update on the company's Misima and Livingstone Gold Projects.
28 Aug 2019 - Ingenia Communities Group Limited (ASX:INA) CFO, Scott Noble discusses the company's FY19 results, its portfolio and the demand for seniors' accommodation.
10 Jun 2021 - Calima Energy Limited (ASX:CE1) Executive Chairman Glenn Whiddon provides an update on production at the company's projects in British Columbia and its plans for an active, low-risk drilling program developing proven reserves.
28 Sep 2022 - Meeka Metals Limited (ASX:MEK) Managing Director and CEO Tim Davidson discusses recent gold and rare earths results and the outlook for the next year.
17 Aug 2022 - CARETEQ Limited (ASX:CTQ) Executive Chairman Mark Simari discusses the company's recent agreement with drug management platform StrongRoom AI and the transition from paper-based to digital record keeping within the aged care and assistive living sector.
16 Jun 2020 - Zelira Therapeutics Limited (ASX:ZLD) Managing Director Ex USA, Dr Richard Hopkins talks about the company's pipeline of products in clinical development targeting insomnia, chronic pain and autism, its model for rapid commercialisation, its go-to-market strategy and first revenues from US licensing partners.